A shorter symptom onset to remdesivir treatment (SORT) interval is associated with a lower mortality in moderate-to-severe COVID-19: A real-world analysis

OBJECTIVES: Remdesivir is the current recommended anti-viral treatment in moderate-to-severe COVID-19. However, data on impact of timing of therapy, efficacy, and safety are limited. We evaluated the impact of timing of remdesivir initiation (symptom onset to remdesivir treatment [SORT] interval) on...

Descripción completa

Detalles Bibliográficos
Autores principales: Mehta, Ravindra M., Bansal, Sameer, Bysani, Suhitha, Kalpakam, Hariprasad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7908839/
https://www.ncbi.nlm.nih.gov/pubmed/33647517
http://dx.doi.org/10.1016/j.ijid.2021.02.092

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7908839/
https://www.ncbi.nlm.nih.gov/pubmed/33647517
http://dx.doi.org/10.1016/j.ijid.2021.02.092

Ejemplares similares